207 related articles for article (PubMed ID: 28812098)
1. [Radiological response assessment of modern immunotherapy using iRECIST].
Persigehl T; Poeppel TD; Sedlaczek O
Radiologe; 2017 Oct; 57(10):826-833. PubMed ID: 28812098
[TBL] [Abstract][Full Text] [Related]
2. Radiological Monitoring of Modern Immunotherapy: A Novel Challenge for Interdisciplinary Patient Care.
Lennartz S; Diederich S; Doehn C; Gebauer B; Grünwald V; Notohamiprodjo M; Sommer W; Schlemmer HP; Persigehl T
Rofo; 2020 Mar; 192(3):235-245. PubMed ID: 31994155
[TBL] [Abstract][Full Text] [Related]
3. Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment.
Lai YC; Chang WC; Chen CB; Wang CL; Lin YF; Ho MM; Cheng CY; Huang PW; Hsu CW; Lin G
Acta Radiol; 2020 Jul; 61(7):983-991. PubMed ID: 31739675
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.
Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M
Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356
[TBL] [Abstract][Full Text] [Related]
5. iRECIST: how to do it.
Persigehl T; Lennartz S; Schwartz LH
Cancer Imaging; 2020 Jan; 20(1):2. PubMed ID: 31900236
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of RECIST 1.1 and iRECIST for Response Evaluation in Solid Tumours].
Houdek Š; Büchler T; Kindlová E
Klin Onkol; 2017; 30(Supplementum3):32-39. PubMed ID: 29239190
[TBL] [Abstract][Full Text] [Related]
7. [Monitoring of immunotherapy : Possibilities and limitations].
Schneider H; Illert AL; Bamberg F; Eisenblätter M
Radiologe; 2020 Aug; 60(8):711-720. PubMed ID: 32710153
[TBL] [Abstract][Full Text] [Related]
8. Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis.
Mulkey F; Theoret MR; Keegan P; Pazdur R; Sridhara R
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32107275
[TBL] [Abstract][Full Text] [Related]
9. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.
Liang H; Xu Y; Chen M; Zhong W; Wang M; Zhao J
Thorac Cancer; 2020 Apr; 11(4):1068-1075. PubMed ID: 32129934
[TBL] [Abstract][Full Text] [Related]
10. iRECIST and atypical patterns of response to immuno-oncology drugs.
Ramon-Patino JL; Schmid S; Lau S; Seymour L; Gaudreau PO; Li JJN; Bradbury PA; Calvo E
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35715004
[TBL] [Abstract][Full Text] [Related]
11. Comparison of RECIST and iRECIST criteria in patients with advanced lung cancer treated with nivolumab.
Singla R; Jajodia A; Agrawal RK; Rao A; Pasricha S; Batra U
J Cancer Res Ther; 2023; 19(5):1212-1218. PubMed ID: 37787285
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy and the role of imaging.
Carter BW; Bhosale PR; Yang WT
Cancer; 2018 Jul; 124(14):2906-2922. PubMed ID: 29671876
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab.
Fukuokaya W; Kimura T; Yanagisawa T; Kimura S; Tsuzuki S; Koike Y; Iwamoto Y; Enei Y; Tanaka M; Urabe F; Onuma H; Honda M; Miki J; Oyama Y; Abe H; Egawa S
BJU Int; 2021 Jan; 127(1):90-95. PubMed ID: 32662189
[TBL] [Abstract][Full Text] [Related]
14. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
Seymour L; Bogaerts J; Perrone A; Ford R; Schwartz LH; Mandrekar S; Lin NU; Litière S; Dancey J; Chen A; Hodi FS; Therasse P; Hoekstra OS; Shankar LK; Wolchok JD; Ballinger M; Caramella C; de Vries EGE;
Lancet Oncol; 2017 Mar; 18(3):e143-e152. PubMed ID: 28271869
[TBL] [Abstract][Full Text] [Related]
15. Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer.
Huicochea Castellanos S; Pagano A; Plodkowski AJ; Girshman J; Hellmann MD; Rizvi H; Flynn J; Zheng J; Capanu M; Halpenny DF; Ginsberg MS
Lung Cancer; 2021 Nov; 161():60-67. PubMed ID: 34536733
[TBL] [Abstract][Full Text] [Related]
16. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.
Tazdait M; Mezquita L; Lahmar J; Ferrara R; Bidault F; Ammari S; Balleyguier C; Planchard D; Gazzah A; Soria JC; Marabelle A; Besse B; Caramella C
Eur J Cancer; 2018 Jan; 88():38-47. PubMed ID: 29182990
[TBL] [Abstract][Full Text] [Related]
17. Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial.
Ahmed FS; Dercle L; Goldmacher GV; Yang H; Connors D; Tang Y; Karovic S; Zhao B; Carvajal RD; Robert C; Maitland ML; Oxnard GR; Schwartz LH
Eur Radiol; 2021 Apr; 31(4):1853-1862. PubMed ID: 32995974
[TBL] [Abstract][Full Text] [Related]
18. The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST.
Inno A; Lo Russo G; Salgarello M; Corrao G; Casolino R; Galli G; Modena A; Romano L; Pusceddu S; Greco FG; Garassino MC; Gori S
Tumori; 2018; 104(2):88-95. PubMed ID: 29714647
[TBL] [Abstract][Full Text] [Related]
19. Response criteria for immunotherapy and the radiologic patterns of immune-related adverse events.
Elsherif SB; Anderson M; Chaudhry AA; Kumar SP; Gopireddy DR; Lall C; Bhosale PR
Eur J Radiol; 2022 Jan; 146():110062. PubMed ID: 34890935
[TBL] [Abstract][Full Text] [Related]
20. Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria.
Vernuccio F; Godfrey D; Meyer M; Williamson HV; Salama JK; Niedzwiecki D; Stephens SJ; Ronald J; Palta M; Marin D
AJR Am J Roentgenol; 2019 Dec; 213(6):1232-1239. PubMed ID: 31613663
[No Abstract] [Full Text] [Related]
[Next] [New Search]
